Minoxidil, an orally effective vasodilator, was successful in lowering blood pressure in 22 patients, followed up for up to 3 yrs, with hypertension refractory to medical management, including both antihypertensive drug combinations and ultrafiltration. In nondialysis patients renal function was preserved and in dialysis patients bilateral nephrectomy was avoided. Although sodium retention and reflex tachycardia were common, they were managed by beta-adrenergic blockade with propranolol and diuresis with furosemide.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
One-touch embeddable microneedles for hair loss treatment.
Int J Pharm
January 2025
Department of Biomaterials Science (BK21 Four Program), Life and Industry Convergence Institute, Pusan National University, Miryang 50463, Republic of Korea. Electronic address:
With increasing clinical demands for painless and easy administration of medications, such as for hair loss, microneedles (MNs) have been widely exploited for facilitating drug permeation in a minimally invasive manner. However, precise dose control and long-term drug delivery without the infection risk through punctured holes have remained unresolved. Herein, we developed swellable microneedles (MNs) with an air-pocket structure, enabling shear-induced implantation inside the skin.
View Article and Find Full Text PDFLow-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement.
JAMA Dermatol
January 2025
Department of Dermatology, University of California, San Francisco.
Article Synopsis
- Small studies suggest that low-dose oral minoxidil (LDOM) might be effective and safe for hair loss, but more extensive research and guidelines are needed.* -
- An expert consensus statement was developed involving 43 dermatologists to standardize LDOM prescribing practices, covering various aspects like indications, dosing, and monitoring.* -
- The consensus reached includes 76 relevant points, but topics related to pediatric use and titration protocols need further investigation, highlighting gaps in research for younger patients.*
Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management.
Arch Dermatol Res
September 2024
The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 East 38th Street, 12th Floor, New York, NY, 10016, USA.
LDOM has enhanced treatment options for female AGA, yet its combined efficacy with therapies such as spironolactone, finasteride, or dutasteride remains inadequately explored. This study aims to compare the efficacy and safety of LDOM in combination with spironolactone versus LDOM with finasteride or dutasteride in women with AGA. Our analysis revealed that both combination therapies produced similar improvements in hair growth and had comparable safety profiles.
View Article and Find Full Text PDFPanax notoginseng saponins loaded W/O microemulsion for alopecia therapy with panthenol as cosurfactant to reduce skin irritation.
Int J Pharm
September 2024
School of Pharmaceutical Sciences, Sun Yat-sen University, University Town, Guangzhou 510006, PR China; State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, PR China; Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, Sun Yat-sen University, University Town, Guangzhou 510006, PR China. Electronic address:
Article Synopsis
- The study highlights the complexity of alopecia treatment and criticizes current therapies for their single-mechanism and long-term side effects.
- A new water-in-oil microemulsion formulation using Panax notoginseng saponins (PNS ME) improves skin penetration and promotes hair growth by enhancing dermal papilla cell mobility and reducing skin irritation.
- PNS ME shows significant therapeutic outcomes for both telogen effluvium and androgenetic alopecia in mice, with promising safety and efficacy compared to traditional treatments like minoxidil.
Hydrogel forming microneedles loaded with VEGF and Ritlecitinib/polyhydroxyalkanoates nanoparticles for mini-invasive androgenetic alopecia treatment.
Bioact Mater
August 2024
Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Department of Life Sciences and Medicine, Northwest University, Xi'an, 710069, China.
Article Synopsis
- Androgenetic alopecia (AGA) is the most common type of hair loss and currently lacks effective treatments due to poor blood vessel formation in the scalp.
- Researchers developed a new treatment method using a hyaluronic acid-based microneedle system (V-R-MNs) that delivers vascular endothelial growth factor (VEGF) and the hair loss drug Ritlecitinib through a minimally invasive process.
- In tests, V-R-MNs showed improved hair growth in mice compared to the usual drug minoxidil, promoting quicker hair regrowth and better hair quality, paving the way for safer and more effective treatments for AGA and similar conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!